The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity
- PMID: 15544917
- DOI: 10.1016/j.freeradbiomed.2004.08.012
The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity
Abstract
The association of paraoxonase-1 (PON1) with high-density lipoproteins (HDL) is a prerequisite for maintaining normal serum activity of the enzyme. The lipoprotein furnishes an amphipathic environment to shield the hydrophobic, N-terminal region of the enzyme, and such an environment may also be necessary for interaction of PON1 with its substrates. HDL provides the optimal physiological acceptor complex, in terms of both stimulating PON1 secretion and stabilizing the secreted peptide. Lipid and peptide components of HDL contribute to these effects, such that modulating HDL composition influences PON1 activity and function. In this context, understanding how PON1 associates with HDL, what governs the association, and the mechanism by which the PON1-HDL complex exerts its antioxidant function is of particular physiological relevance. Moreover, HDL is subject to substantial compositional variations under both normal and pathological metabolic conditions. It has implications for the influence of the enzyme on cardiovascular risk, as normal enzyme activity may not correlate with optimal functional (antioxidant) efficiency. We review evidence that HDL lipid and protein components interact to promote PON1 secretion and maintain serum enzyme activity. Emerging data on how the enzyme associates with HDL are discussed, and the consequences for PON1 function of modifications to HDL are outlined. Finally, we highlight questions concerning the HDL-PON1 association that remain unanswered but are of particular importance in defining PON1 efficiency.
Similar articles
-
ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.Biochemistry. 2010 Jan 26;49(3):532-8. doi: 10.1021/bi9013227. Biochemistry. 2010. PMID: 20025294
-
Variation in paraoxonase-1 activity and atherosclerosis.Curr Opin Lipidol. 2009 Aug;20(4):265-74. doi: 10.1097/MOL.0b013e32832ec141. Curr Opin Lipidol. 2009. PMID: 19550323 Review.
-
Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.Atherosclerosis. 2006 Jul;187(1):74-81. doi: 10.1016/j.atherosclerosis.2005.08.026. Epub 2005 Oct 17. Atherosclerosis. 2006. PMID: 16229851
-
Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells.Atherosclerosis. 2005 Mar;179(1):17-25. doi: 10.1016/j.atherosclerosis.2004.08.039. Epub 2004 Dec 7. Atherosclerosis. 2005. PMID: 15721005
-
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis].Rev Esp Cardiol. 2004 Jun;57(6):557-69. Rev Esp Cardiol. 2004. PMID: 15225502 Review. Spanish.
Cited by
-
Serum Activities of Paraoxonase 1 (PON1) in Predicting Liver Damage Among Patients Diagnosed With Hepatocellular Carcinoma: A Case-Control Study.Cureus. 2023 Sep 29;15(9):e46234. doi: 10.7759/cureus.46234. eCollection 2023 Sep. Cureus. 2023. PMID: 37908943 Free PMC article.
-
A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease.Pharmaceutics. 2023 May 15;15(5):1504. doi: 10.3390/pharmaceutics15051504. Pharmaceutics. 2023. PMID: 37242746 Free PMC article. Review.
-
Association of Paraoxonase-1 and NT-proBNP with Clinical, Clinico-Pathologic and Echocardiographic Variables in Dogs with Mitral Valve Disease.Vet Sci. 2023 Jan 1;10(1):33. doi: 10.3390/vetsci10010033. Vet Sci. 2023. PMID: 36669034 Free PMC article.
-
Phytochemicals as Modulators of Paraoxonase-1 in Health and Diseases.Antioxidants (Basel). 2022 Jun 27;11(7):1273. doi: 10.3390/antiox11071273. Antioxidants (Basel). 2022. PMID: 35883764 Free PMC article. Review.
-
Effects of combined physical exercise on plasma lipid variables, paraoxonase 1 activity, and inflammation parameters in adults with obesity: a randomized clinical trial.J Endocrinol Invest. 2022 Oct;45(10):1991-1997. doi: 10.1007/s40618-022-01833-3. Epub 2022 Jun 17. J Endocrinol Invest. 2022. PMID: 35713846 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous